BPC-157 — Research Reference

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a partial sequence of human gastric juice protein BPC and has been investigated in numerous preclinical studies for its effects on tissue repair, gastrointestinal function, and inflammatory response.

Quick Reference

Overview

BPC-157 was first described in research conducted at the University of Zagreb. The compound has been investigated extensively in rodent models, with studies examining its potential role in healing of tendons, ligaments, muscle tissue, bone, intestinal lining, and peripheral nerves. A small number of human trials have examined its effects on inflammatory bowel conditions.

Research has investigated BPC-157 for its potential role in modulating angiogenesis (the formation of new blood vessels), upregulating growth factor receptors, and interacting with the nitric oxide (NO) system. Its gastric origin is consistent with the observation that the compound appears to be stable in gastric acid at physiological concentrations.

BPC-157 is not currently approved for human therapeutic use in any major jurisdiction and is classified as a research chemical in most countries.

Reported Protocols

The following information represents commonly reported research ranges drawn from published anecdotal accounts and preclinical literature. These are not medical recommendations.

Subcutaneous and Intramuscular Protocols

Subcutaneous injection is the most commonly reported administration route in anecdotal research accounts. Commonly reported doses range from 200 mcg to 500 mcg per day, administered once or twice daily.

• Low range: 1–2 mcg/kg body weight per day (approximately 80–160 mcg for a 80 kg subject)
• Mid range: 250–500 mcg per day, split into two administrations
• Duration: Commonly reported cycles range from 4 to 8 weeks

Intramuscular injection is also reported, particularly when researchers are targeting specific muscle or tendon tissue. The reported dosing ranges are similar to subcutaneous protocols.

Oral Administration

Anecdotal reports suggest that oral administration of BPC-157 may produce gastrointestinal effects even at lower systemic bioavailability, consistent with its gastric origin. Commonly reported oral doses range from 500 mcg to 1,000 mcg per day.

Oral bioavailability in systemic circulation is reported to be lower than parenteral routes, though some researchers suggest this may be adequate for GI-targeted research.

Reported Effects

The following effects have been reported in preclinical research and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes.

Tissue Repair & Healing

Animal studies have investigated BPC-157 for potential effects on:

• Tendon healing and regeneration (Achilles tendon models)
• Ligament repair (ACL and other ligamentous tissue)
• Muscle injury recovery
• Wound healing (dermal and surgical wounds)
• Bone repair

Multiple rodent studies have reported accelerated healing across these tissue types, with researchers proposing angiogenesis and growth factor upregulation as possible mechanisms.

Gastrointestinal Effects

Research has investigated BPC-157 for its potential role in:

• Inflammatory bowel conditions (Crohn’s disease models, ulcerative colitis models)
• NSAID-induced gastrointestinal damage
• Intestinal anastomosis healing
• Gastric ulcer resolution

The compound’s stability in gastric acid has been noted as a relevant pharmacological property for oral administration research.

Neurological

Animal research has investigated BPC-157 for potential neuroprotective effects, including models of traumatic brain injury and peripheral nerve damage. Some researchers have also reported observations related to dopaminergic and serotonergic system interactions.

Anti-inflammatory

Anecdotal reports and some preclinical data suggest anti-inflammatory activity, though the precise mechanism remains under investigation.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Theoretical concern: BPC-157 is reported to be pro-angiogenic. Some researchers have raised the theoretical question of whether pro-angiogenic compounds could influence tumor vascularity in subjects with pre-existing neoplastic disease. This has not been demonstrated in short-term research, but is considered a relevant discussion point for completeness.

The compound has not undergone comprehensive human safety trials.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Room temperature: Reported stable for up to 3 months when kept away from light and moisture
• Refrigerator (2–8°C): Preferred for extended storage; commonly reported stable for 12 months or more
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles of the dry powder
• Light sensitivity: Store in an opaque or amber vial; avoid direct light exposure

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze a reconstituted solution — freezing degrades the peptide and may cause aggregation
• Bacteriostatic water (BAC water) is the recommended diluent; the benzyl alcohol preservative inhibits bacterial growth and extends refrigerated shelf life vs sterile water
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly to the lyophilized vial, directing liquid along the side of the vial rather than directly onto the peptide powder. Swirl gently — do not shake. Allow a few minutes for complete dissolution.

See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

Is BPC-157 approved for human use? BPC-157 is not approved for human therapeutic use by the FDA, EMA, or TGA as of the most recent update to this page. It is classified as a research chemical and is not available as a pharmaceutical drug in any major market.

What is the difference between subcutaneous and oral BPC-157? Subcutaneous injection delivers the peptide directly into systemic circulation, bypassing first-pass metabolism. Oral administration may be sufficient for gastrointestinal-targeted research, as the compound is reported to exhibit partial stability in gastric acid. For systemic effects, parenteral routes are generally considered the more reliable option in anecdotal research accounts.

Can BPC-157 be stacked with TB-500? This combination is commonly discussed in healing-focused research contexts. See the BPC-157 + TB-500 Stack Guide for reported protocols.

How should BPC-157 be dosed relative to body weight? Some researchers use a weight-based approach of approximately 1–2 mcg/kg per day. Others use a fixed dose of 250–500 mcg per day regardless of body weight. Both approaches appear in the anecdotal literature.

Related Pages

Goals: Recovery & Healing · Inflammation · Gut Health · Skin & Hair · Performance

Comparisons: BPC-157 vs TB-500 · BPC-157 vs GHK-Cu · BPC-157 vs KPV

Stacks: Wolverine · GLOW · KLOW

References & Further Reading

The following publicly available research is frequently cited in BPC-157 literature. This list is not exhaustive.

• Sikiric P, et al. (2018). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Neuropharmacology, 16(10), 1523–1548. PubMed →
• Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. PubMed →
• Sikiric P, et al. (2014). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 20(7), 1126–1138. PubMed →